New prognostic markers in neuroblastoma

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 6, 2012, Pages 555-567

  Navarro, Samuel ^a   Piqueras, Marta ^a   Villamón, Eva ^a   Yáñez, Yania ^b   Balaguer, Julia ^b   Cañete, Adela ^b   Noguera, Rosa ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Biomarkers; Meta classifier; Neuroblastoma; Prognosis

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CATECHOLAMINE; DOPAMINE BETA MONOOXYGENASE; MYC PROTEIN; TUMOR MARKER; TYROSINE 3 MONOOXYGENASE;

AGE DISTRIBUTION; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE URINE LEVEL; CELL INTERACTION; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 17; CHROMOSOME ARM; CLINICAL FEATURE; EPIGENETICS; GANGLIONEUROMA; GENE DOSAGE; GENE EXPRESSION; GENETIC RISK; HEREDITY; HISTOPATHOLOGY; HUMAN; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; REVIEW; RISK ASSESSMENT; SCINTIGRAPHY; STROMA CELL; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT;

EID: 84867922031     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.704018     Document Type: Review

References (106)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3(3):203-16
2. Spix C, Pastore G, Sankila R, et al. Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42(13):2081-91
3. van Noesel MM, Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene 2004;325:1-15
4. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27(2):289-97
5. Ora I, Eggert A. Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol 2011;21(4):217-28
6. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11(8):1466-77
7. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27(2):298-303
8. Evans AE. Staging and treatment of neuroblastoma. Cancer 1980;45(7 Suppl):1799-802
9. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31(12):2098-103
10. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23(27):6459-65
11. Miettinen M, Chatten J, Paetau A, Stevenson A. Monoclonal antibody NB84 in the differential diagnosis of neuroblastoma and other small round cell tumors. Am J Surg Pathol 1998;22(3):327-32
12. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92(9):2451-61
13. PeuchmaurM, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98(10):2274-81
14. Burgues O, Navarro S, Noguera R, et al. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stromapoor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch 2006;449(4):410-20
15. Navarro S, Amann G, Beiske K, et al. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. J Clin Oncol 2006;24(4):695-9
16. Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009;100(9):1471-82
17. Piqueras M, Navarro S, Canete A, et al. Prognostic value of partial genetic instability in neuroblastoma with
18. Kryh H, Caren H, Erichsen J, et al. Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics 2011;12:443
19. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol 2010;28(19):3122-30
20. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27(7):1026-33
21. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224(4653):1121-4
22. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313(18):1111-16
23. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353(21):2243-53
24. Caren H, Kryh H, Nethander M, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA 2010;107(9):4323-8
25. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369(9579):2106-20
26. Henrich KO, Bauer T, Schulte J, et al. CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. Cancer Res 2011;71(8):3142-51
27. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23(27):6466-73
28. Schneiderman J, London WB, Brodeur GM, et al. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol 2008;26(6):913-18
29. Kaneko Y, Knudson AG. Mechanism and relevance of ploidy in neuroblastoma. Genes Chromosomes Cancer 2000;29(2):89-95
30. Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261(1):243-57
31. Naranjo A, Parisi MT, Shulkin BL, et al. Comparison of (1)(2)(3)Imetaiodobenzylguanidine (MIBG) and (1)(3)(1)I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011;56(7):1041-5
32. Messina JA, Cheng SC, Franc BL, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47(7):865-74
33. Piccardo A, Lopci E, Conte M, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 2012;39(1):57-71
34. Swerts K, Ambros PF, Brouzes C, et al. Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. J Histochem Cytochem 2005;53(12):1433-40
35. Kryh H, Abrahamsson J, Jegeras E, et al. MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma. Int J Oncol 2011;39(5):1063-71
36. Burchill SA, Kinsey SE, Picton S, et al. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 2001;36(1):213-19
37. Oltra S, Martinez F, Orellana C, et al. The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn Mol Pathol 2005;14(1):53-7
38. Viprey VF, Lastowska MA, Corrias MV, et al. Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol 2008;216(2):245-52
39. Corrias MV, Parodi S, Haupt R, et al. Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma. Br J Cancer 2008;98(2):263-9
40. Yanez Y, Grau E, Oltra S, et al. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. J Cancer Res Clin Oncol 2011;137(8):1263-72
41. Ambros IM, Hata J, Joshi VV, et al. Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer 2002;94(5):1574-83
42. Tornoczky T, Semjen D, Shimada H, Ambros IM. Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/ poorly differentiated neuroblastoma. Pathol Oncol Res 2007;13(4):269-75
43. Sano H, Gonzalez-Gomez I, Wu SQ, et al. A case of composite neuroblastoma composed of histologically and biologically distinct clones. Pediatr Dev Pathol 2007;10(3):229-32
44. Amar P, Ballet P, Barlovatz-Meimon G, et al. Hyperstructures, genome analysis and I-cells. Acta Biotheor 2002;50(4):357-73
45. Huang S, Ingber DE. A non-genetic basis for cancer progression and metastasis: self-organizing attractors in cell regulatory networks. Breast Dis 2006;26:27-54
46. Noguera R, Nieto OA, Tadeo I, et al. Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histol Histopathol 2012;27(6):693-705
47. Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 2011;21(4):229-37
48. Pietras A, Hansford LM, Johnsson AS, et al. HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci USA 2009;106(39):16805-10
49. Lam WA, Cao L, Umesh V, et al. Extracellular matrix rigidity modulates neuroblastoma cell differentiation and N-myc expression. Mol Cancer 2010;9:35
50. Villamon E, Piqueras M, Berbegall AP, et al. Comparative study of MLPA-FISH to determine DNA copy number alterations in neuroblastic tumors. Histol Histopathol 2011;26(3):343-50
51. Vandesompele J, Michels E, De Preter K, et al. Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. Int J Cancer 2008;122(5):1177-82
52. Combaret V, Bergeron C, Noguera R, et al. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol 2005;23(34): 8919-20; author reply 20
53. Yagyu S, Iehara T, Gotoh T, et al. Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: a novel diagnostic tool for therapy stratification of neuroblastoma. Cancer Lett 2011;309(2):185-9
54. Savelyeva L, Corvi R, Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet 1994;55(2):334-40
55. Van Roy N, Laureys G, Cheng NC, et al. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 1994;10(2):103-14
56. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340(25):1954-61
57. Janoueix-Lerosey I, Penther D, Thioux M, et al. Molecular analysis of chromosome arm 17q gain in neuroblastoma. Genes Chromosomes Cancer 2000;28(3):276-84
58. Combaret V, Brejon S, Iacono I, et al. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer 2011;56(5):757-61
59. Ambros IM, Brunner B, Aigner G, et al. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res 2011;17(4):792-804
60. Schleiermacher G, Michon J, Ribeiro A, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer 2011;105(12):1940-8
61. Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483(7391):589-93
62. Maris JM, Mosse YP, Bradfield JP, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008;358(24):2585-93
63. Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009;41(6):718-23
64. Wang K, Diskin SJ, Zhang H, et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 2011;469(7329):216-20
65. Nguyen le B, Diskin SJ, Capasso M, et al. Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet 2011;7(3):e1002026
66. Diskin SJ, Hou C, Glessner JT, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009;459(7249):987-91
67. Hiyama E, Hiyama K, Yokoyama T, et al. Length of telomeric repeats in neuroblastoma: correlation with prognosis and other biological characteristics. Jpn J Cancer Res 1992;83(2):159-64
68. Ohali A, Avigad S, Ash S, et al. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006;107(6):1391-9
69. Lundberg G, Sehic D, Lansberg JK, et al. Alternative lengthening of telomeres-an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer 2011;50(4):250-62
70. Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307(10):1062-71
71. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455(7215):967-70
72. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455(7215):930-5
73. Subramaniam MM, Piqueras M, Navarro S, Noguera R. Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas. Hum Pathol 2009;40(11):1638-42
74. McConville C, Reid S, Baskcomb L, et al. PHOX2B analysis in non-syndromic neuroblastoma cases shows novel mutations and genotype-phenotype associations. Am J Med Genet A 2006;140(12):1297-301
75. Reiff T, Tsarovina K, Majdazari A, et al. Neuroblastoma phox2b variants stimulate proliferation and dedifferentiation of immature sympathetic neurons. J Neurosci 2010;30(3):905-15
76. Bachetti T, Di Paolo D, Di Lascio S, et al. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. PLoS One 2010;5(10):e13108
77. Berthier A, Piqueras M, Villamon E, et al. Anaplastic lymphoma kinase expression in neuroblastomas and its relationship with genetic, prognostic, and predictive factors. Hum Pathol 2011;42(2):301-2
78. Schulte JH, Horn S, Schlierf S, et al. MicroRNAs in the pathogenesis of neuroblastoma. Cancer Lett 2009;274(1):10-15
79. Gomez-Mateo Mdel C, Piqueras M, Pahlman S, et al. Prognostic value of SOX2 expression in neuroblastoma. Genes Chromosomes Cancer 2011;50(5):374-7
80. Sartelet H, Imbriglio T, Nyalendo C, et al. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology 2012;60(7):1144-55
81. Lamers F, Schild L, Koster J, et al. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer 2012;48(5):763-71
82. Bowen KA, Chung DH. Recent advances in neuroblastoma. Curr Opin Pediatr 2009;21(3):350-6
83. Lammens T, Swerts K, Derycke L, et al. N-cadherin in neuroblastoma disease: expression and clinical significance. PLoS One 2012;7(2):e31206
84. Holzel M, Huang S, Koster J, et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010;142(2):218-29
85. Huang S, Laoukili J, Epping MT, et al. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009;15(4):328-40
86. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24(31):5070-8
87. Fardin P, Barla A, Mosci S, et al. A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Mol Cancer 2010;9:185
88. Gowda M, Godder K, Kmieciak M, et al. Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med 2011;9:170
89. Oberthuer A, Hero B, Berthold F, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28(21):3506-15
90. Vermeulen J, De Preter K, Naranjo A, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10(7):663-71
91. De Preter K, Vermeulen J, Brors B, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010;16(5):1532-41
92. Abel F, Dalevi D, Nethander M, et al. A 6-gene signature identifies four molecular subgroups of neuroblastoma. Cancer Cell Int 2011;11:9
93. De Preter K, De Brouwer S, Van Maerken T, et al. Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clin Cancer Res 2009;15(11):3690-6
94. Wei JS, Johansson P, Chen QR, et al. MicroRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009;15(17):5560-8
95. Guo J, Dong Q, Fang Z, et al. Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. Cancer Biol Ther 2010;9(6):446-52
96. Stallings RL. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des 2009;15(4):456-62
97. Schulte JH, Schowe B, Mestdagh P, et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 2010;127(10):2374-85
98. Lin RJ, Lin YC, Chen J, et al. MicroRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 2010;70(20):7841-50
99. Buckley PG, Alcock L, Bryan K, et al. Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q-neuroblastoma. Clin Cancer Res 2010;16(11):2971-8
100. De Preter K, Mestdagh P, Vermeulen J, et al. MiRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res 2011;17(24):7684-92
101. Alaminos M, Davalos V, Cheung NK, et al. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004;96(16):1208-19
102. Abe M, Watanabe N, McDonell N, et al. Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 2008;74(1-2):50-60
103. Grau E, Martinez F, Orellana C, et al. Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog 2011;50(3):153-62
104. Michalowski MB, de Fraipont F, Plantaz D, et al. Methylation of tumor-suppressor genes in neuroblastoma: the RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer 2008;50(1):29-32
105. Yang Q, Kiernan CM, Tian Y, et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007;13(11):3191-7
106. Misawa A, Tanaka S, Yagyu S, et al. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br J Cancer 2009;100(2):399-404